Adalimumab biosimilar - Coherus BioSciences

Drug Profile

Adalimumab biosimilar - Coherus BioSciences

Alternative Names: CHS-1420

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Plaque psoriasis

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 08 Aug 2018 Adalimumab biosimilar - Coherus BioSciences is available for licensing in World (excluding USA) as of 08 Aug 2018. www.coherus.com
  • 08 Mar 2018 Coherus BioSciences intends to launch the product in 2022
  • 31 Dec 2017 Coherus BioSciences enters into a distribution agreement with Orox Pharmaceuticals for etanercept biosimilar in Caribbean (West Indies) and Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top